Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Glioblastoma 49Breast Neoplasms 49Prostatic Neoplasms 47Carcinoma, Non-Small-Cell Lung 47Squamous Cell Carcinoma of Head and Neck 37Lung Neoplasms 29Head and Neck Neoplasms 26Glioma 22Rectal Neoplasms 21Sarcoma 20Neoplasms 20Brain Neoplasms 20Oropharyngeal Neoplasms 16Esophageal Neoplasms 15Uterine Cervical Neoplasms 14Neoplasm Metastasis 14Astrocytoma 13Triple Negative Breast Neoplasms 12Esophageal Squamous Cell Carcinoma 12Carcinoma, Hepatocellular 12Pancreatic Neoplasms 11Melanoma 11Gliosarcoma 10Colorectal Neoplasms 10Stomach Neoplasms 9Small Cell Lung Carcinoma 9Lymphoma 9Hodgkin Disease 9Carcinoma, Squamous Cell 9Urinary Bladder Neoplasms 8

Interventions

Radiotherapy 1Leucovorin 1Fluorouracil 1Cetuximab 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Locally Recurrent Rectal Cancer × Radiotherapy × 1 year × Clear all
NCT07183865 2025-09-19

Hypofractionated Radiotherapy Combined With NALIRIF, PD-1 Antibody in Locally Recurrent Rectal Cancer(NOVELTY-R)

Fudan University

Phase 2 Recruiting
44 enrolled
Gastrointestinal

Locally Recurrent Rectal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡